Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $70 from $75 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
- Haemonetics receives FDA clearance for NexSys PCS Plasma Collection System
- Haemonetics Releases 2024-2025 Corporate Responsibility Report
- Haemonetics Earnings Call: Strong Core, IVT Drag
- Haemonetics price target lowered to $81 from $99 at Baird